Product Description
Theliatinib (HMPL-309) is a new constructive, high effective, high selective, EGFR tyrosine kinase inhibitor. Theliatinib has demonstrated strong inhibitory effects on multiple tumors with overexpressed EGFR or sensitive EGFR mutations. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02601248)
Mechanisms of Action: EGFR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: HUTCHMED
Company Location: HONG KONG K3 00000
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Esophageal Cancer|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| HMPL-309 | P1 |
Terminated |
Esophageal Cancer |
2018-12-01 |
42% |
| CTR20130956 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2016-07-06 |
|
| 2010-309-00CH1 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2016-02-01 |
41% |